Antisense Oligonucleotide Brain Delivery

Antisense Oligonucleotide (ASO) Delivery to Brain

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Antisense Oligonucleotide Brain Delivery</th>
</tr>
<tr>
<td class="label">Generation</td>
<td>Modifications</td>
</tr>
<tr>
<td class="label">1st</td>
<td>Phosphorothioate (PS) backbone</td>
</tr>
<tr>
<td class="label">2nd</td>
<td>2'-O-methyl, 2'-O-methoxyethyl (MOE)</td>
</tr>
<tr>
<td class="label">3rd</td>
<td>Locked Nucleic Acid (LNA), PNA, PMO</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tominersen (RG6042)</td>
<td>HTT</td>
</tr>
<tr>
<td class="label">BIIB080 (IONIS-MAPT)</td>
<td>[MAPT](/genes/mapt)</td>
</tr>
<tr>
<td class="label">ION363 (Jacifusen)</td>
<td>FUS</td>
</tr>
<tr>
<td class="label">WVE-004</td>
<td>[C9orf72](/entities/c9orf72)</td>
</tr>
<tr>
<td class="label">BIIB078</td>
<td>C9orf72</td>
</tr>
<tr>
<td class="label">RO7065031</td>
<td>SNCA</td>
</tr>
<tr>
<td class="label">Method</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Intrathecal</td>
<td>Direct CSF access, established</td>
</tr>
<tr>
<td class="label">Intracerebroventricular</td>
<td>Broader CNS distribution</td>
</tr>
<tr>
<td class="label">Convection-Enhanced Delivery</td>
<td>Bulk flow distribution</td>
</tr>
<tr>
<td class="label">Modality</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">AS

...

Antisense Oligonucleotide (ASO) Delivery to Brain

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Antisense Oligonucleotide Brain Delivery</th>
</tr>
<tr>
<td class="label">Generation</td>
<td>Modifications</td>
</tr>
<tr>
<td class="label">1st</td>
<td>Phosphorothioate (PS) backbone</td>
</tr>
<tr>
<td class="label">2nd</td>
<td>2'-O-methyl, 2'-O-methoxyethyl (MOE)</td>
</tr>
<tr>
<td class="label">3rd</td>
<td>Locked Nucleic Acid (LNA), PNA, PMO</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tominersen (RG6042)</td>
<td>HTT</td>
</tr>
<tr>
<td class="label">BIIB080 (IONIS-MAPT)</td>
<td>[MAPT](/genes/mapt)</td>
</tr>
<tr>
<td class="label">ION363 (Jacifusen)</td>
<td>FUS</td>
</tr>
<tr>
<td class="label">WVE-004</td>
<td>[C9orf72](/entities/c9orf72)</td>
</tr>
<tr>
<td class="label">BIIB078</td>
<td>C9orf72</td>
</tr>
<tr>
<td class="label">RO7065031</td>
<td>SNCA</td>
</tr>
<tr>
<td class="label">Method</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Intrathecal</td>
<td>Direct CSF access, established</td>
</tr>
<tr>
<td class="label">Intracerebroventricular</td>
<td>Broader CNS distribution</td>
</tr>
<tr>
<td class="label">Convection-Enhanced Delivery</td>
<td>Bulk flow distribution</td>
</tr>
<tr>
<td class="label">Modality</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">ASO</td>
<td>RNase H or steric block</td>
</tr>
<tr>
<td class="label">siRNA</td>
<td>RNA-induced silencing</td>
</tr>
<tr>
<td class="label">miRNA mimics/inhibitors</td>
<td>Modulate miRNA activity</td>
</tr>
<tr>
<td class="label">Splice-switching</td>
<td>Pre-mRNA splicing modulation</td>
</tr>
</table>

Introduction

Antisense Oligonucleotide Brain Delivery is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Antisense oligonucleotides (ASOs) are short, synthetic single-stranded DNA or RNA molecules designed to modulate gene expression by binding to complementary messenger RNA (mRNA) sequences. ASO-based therapeutics represent one of the most advanced approaches for direct genetic intervention in the central nervous system (CNS), offering precise targeting of disease-causing proteins while avoiding the risks associated with viral vector delivery.

Overview

Antisense oligonucleotide (ASO) therapy represents one of the most promising approaches for treating neurodegenerative diseases by directly targeting disease-causing genes at their source. Unlike small molecule drugs that must interact with protein targets, ASOs can be designed to selectively bind to any messenger RNA (mRNA) sequence, thereby reducing production of toxic proteins or modulating splicing patterns.

The key advantages of ASO therapeutics include:

• High specificity: Designed to bind to a single complementary mRNA sequence
• Versatile mechanisms: Can reduce protein levels (via RNase H) or modulate splicing (steric block)
• Long-lasting effects: With half-lives of months in CSF, ASOs enable infrequent dosing
• Reversible modulation: Effects are reversible upon drug clearance, allowing for treatment flexibility

This page provides comprehensive coverage of ASO delivery methods, mechanisms of action, clinical trials, and emerging therapeutic applications for neurodegenerative diseases including Alzheimer's, Parkinson's, Huntington's, and ALS.

Mechanism of Action

ASOs exert their effects through two primary mechanisms:

RNase H-Dependent Degradation: ASOs designed with a DNA-like backbone recruit RNase H, an endogenous enzyme that cleaves the RNA strand of DNA-RNA hybrids. This leads to degradation of the target mRNA and subsequent reduction in protein production["@rigo2020"].

Steric Block Mechanism: ASOs designed with modified backbones (e.g., morpholinos, LNAs) do not recruit RNase H but instead physically block translational initiation, splice sites, or miRNA binding sites, modulating gene expression without degrading the target mRNA["@karkare2021"].

ASO Chemistry Generations

The development of ASO chemistry has progressed through multiple generations, each improving stability, binding affinity, and therapeutic potential:

Phosphorothioate (PS) backbone: The substitution of sulfur for non-bridging oxygen in the phosphate group provides nuclease resistance and enables RNase H recruitment[@eckstein2014].

2'-O-methoxyethyl (MOE): This modification at the 2' position of the ribose sugar significantly increases binding affinity to target RNA while reducing off-target effects and improving pharmacokinetics[@bennett2017].

Locked Nucleic Acid (LNA): LNAs contain a methylene bridge connecting the 2'-O and 4'-C atoms, locking the ribose in the C3'-endo conformation. This dramatically increases thermal stability and allows for shorter ASO sequences[@veedu2010].

FDA-Approved CNS ASOs

Two ASO therapeutics have received FDA approval for CNS indications:

Nusinersen (Spinraza)

Approved in 2016 for spinal muscular atrophy (SMA), nusinersen targets the SMN2 gene to increase production of functional survival motor neuron (SMN) protein[@finkel2017].

• Mechanism: Steric block – binds to an intronic splice silencer in SMN2 pre-mRNA, promoting inclusion of exon 7
• Delivery: Intrathecal administration every 4 months
• Efficacy: Significant improvement in motor function and survival in infants and children with SMA
• Clinical Trials: ENDEAR (phase 3), CHERISH (phase 3)

Tofersen (Qalsody2023 for SOD)

Approved in 1-associated amyotrophic lateral sclerosis (ALS), tofersen represents the first gene-silencing therapy for ALS[@miller2020].

• Mechanism: RNase H-dependent degradation of SOD1 mRNA
• Delivery: Intrathecal administration every 28 days
• Efficacy: Reduced SOD1 protein in CSF, trend toward slower clinical decline in early-stage patients
• Clinical Trials: VALOR (phase 3), ATLAS (pre-symptomatic)

Clinical Pipeline

Multiple ASO candidates are in clinical development for neurodegenerative diseases:

Tominersen (HTT)

The [huntingtin](genes/htt) (HTT) gene ASO was evaluated in the GENERATION HD1 trial for early-stage Huntington's disease. Despite reducing mutant [huntingtin protein](/proteins/huntingtin) by 40%, the trial was discontinued in 2021 due to lack of clinical benefit compared to placebo[@tabrizi2019]. This outcome highlighted the challenges of treating neurodegeneration after symptom onset.

BIIB080 (MAPT)

Targeting microtubule-associated protein tau (MAPT), this ASO aims to reduce [tau protein](/proteins/tau) production in Alzheimer's disease. Phase 1/2 results showed dose-dependent reduction in total tau and phospho-tau in CSF[@mummadi2022].

ION363 (FUS-ALS)

Fused in sarcoma (FUS) mutations cause a aggressive form of ALS. ION363 has shown promise in reducing FUS protein in preclinical models and is now in clinical testing for FUS-ALS patients[@korobeynikov2022].

Pharmacokinetics

Understanding ASO distribution is critical for CNS delivery:

Intrathecal Administration

• CSF Distribution: After intrathecal injection, ASOs distribute throughout the cerebrospinal fluid compartments
• Parenchymal Penetration: Limited by diffusion – concentrations decrease with distance from the injection site
• Half-life in CSF: 3-6 months for PS-modified ASOs, enabling infrequent dosing
• Tissue Exposure: Maximum brain tissue concentrations achieved after 2-4 doses

Cellular Uptake Mechanisms

ASOs enter [neurons](/entities/neurons) and glia through multiple mechanisms:

Clathrin-mediated endocytosis: Primary route for cellular uptake

Macropinocytosis: Fluid-phase uptake, particularly in activated [microglia](/entities/microglia)

Direct membrane translocation: Limited for highly modified ASOs

Once inside cells, ASOs accumulate in endosomes and gradually release into the cytoplasm and nucleus where they engage their targets[@geary2015].

Next-Generation Delivery Strategies

Conjugated ASOs

Chemical conjugation can enhance tissue-specific delivery:

• Fatty acid conjugation: Increases membrane permeability and tissue retention
• Peptide conjugation: Cell-penetrating peptides (CPPs) facilitate cellular uptake
• Antibody conjugation: Targeting specific cell surface receptors enables cell-type-specific delivery[@juliano2016]

CNS-Penetrant ASOs from Systemic Delivery

Systemic administration faces the challenge of crossing the blood-brain barrier (BBB). Newer chemistries aim to enable peripheral administration with CNS penetration:

• Trivalent N-acetylgalactosamine (GalNAc): Enables liver delivery but not [BBB](/entities/blood-brain-barrier) crossing
• Novel chemistries: Reduced charge and optimized physicochemical properties may enable limited BBB penetration

Direct CNS Delivery Methods

Safety Considerations

Off-Target Effects

ASOs can hybridize to unintended transcripts, particularly when there is partial sequence complementarity. Mitigation strategies include:

• Comprehensive bioinformatics screening for off-target matches
• Chemical modifications that reduce RNase H activity on non-target RNAs
• Lowering doses while maintaining efficacy

Immune Activation

PS-modified ASOs can activate innate immune responses through toll-like receptor (TLR) binding. Strategies to reduce immunogenicity include:

• Minimal PS backbone modifications
• High-purity manufacturing
• Pre-medication with corticosteroids in some trials

CSF Findings

White blood cell pleocytosis and elevated protein are commonly observed after intrathecal ASO administration but are generally transient and not clinically significant[@hach2021].

Comparison with Other RNA Therapeutics

Background

The study of Antisense Oligonucleotide Brain Delivery has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Intrathecal Drug Delivery](/therapeutics/intrathecal-drug-delivery)
• [AAV Gene Therapy for Neurodegeneration](/investment/gene-therapy-neurodegeneration)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/diseases/huntingtons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Tau Proteins](/content/proteins)
• [SOD1](/cell-types/sod1-mutant-motor)
• [FUS Gene](/mechanisms/fus-als-ftd-causal-chain)

External Links

• [ClinicalTrials.gov - ASO trials](https://clinicaltrials.gov)
• [Ionis Pharmaceuticals](https://www.ionispharma.com)
• [Biogen ALS pipeline](https://www.biogen.com)

References

[Rigo F, Seth PP, Bennett CF, Antisense oligonucleotide-based therapies for diseases of the nervous system (2020)](https://doi.org/10.1038/s41573-020-0070-0))

Karkare S, Bhatnagar D, Promising RNA interference (RNAi)-based therapies for amyotrophic lateral sclerosis (2021)

[Eckstein F, Phosphorothioates, essential components of therapeutic oligonucleotides (2014)](https://doi.org/10.1089/nat.2014.0506))

Bennett CF, Baker BF, Pham N, et al, Pharmacology of 2'-O-methoxyethyl containing antisense oligonucleotides (2017)

[Veedu RN, Wengel J, Locked nucleic acids: promising nucleic acid analogs for therapeutic applications (2010)](https://doi.org/10.1002/cbdv.200900343))

[Finkel RS, Mercuri E, Darras BT, et al, Nusinersen versus sham control in infantile-onset spinal muscular atrophy (2017)](https://doi.org/10.1056/nejmoa1702752))

[Miller T, Cudkowicz M, Shaw PJ, et al, Phase 1-2 trial of tofersen for SOD1 ALS (2020)](https://doi.org/10.1056/nejmoa2003715))

[Tabrizi SJ, Leavitt BR, Landles C, et al, Targeting huntingtin expression in patients with Huntington's disease (2019)](https://doi.org/10.1056/nejmoa1900907))

Mummadi S, et al, BIIB080 (IONIS-MAPT): results from a phase 1/2 study (2022)

[Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B, et al, Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in FUS-ALS (2022)](https://doi.org/10.1038/s41591-021-01615-z))

[Geary RS, Norris D, Yu R, Bennett CF, Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides (2015)](https://doi.org/10.1016/j.addr.2015.01.008))

[Juliano RL, The delivery of therapeutic oligonucleotides (2016)](https://doi.org/10.1093/nar/gkw236))

Haché M, Swoboda KJ, Sethna N, et al, Intrathecal injections in children with spinal muscular atrophy: single-center experience (2021)

Senn R, Saleeb R, Liu H, et al, Antisense oligonucleotides targeting C9orf72 (2022)

[Hua Y, Sahashi K, Hung G, et al, Antisense correction of SMN2 splicing in the CNS rescues SMA in mice (2010)](https://doi.org/10.1101/gad.1941310))

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: DRD2/SNCA
• [Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SNCA, HSPA1A, DNMT1
• [Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TLR4, SNCA
• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD

Related Analyses:

• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;
• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;